Kruti Joshi, MPH, MD

Understanding Profiles of Patients with Treatment-resistant Depression by Stringency of Health Plan Prior Authorization Criteria for Approval of Esketamine

In the United States, some health plans have more stringent prior authorization (PA) criteria for esketamine insurance coverage for treatment-resistant depression (TRD), requiring more th...

Kruti Joshi , MPH, MD;

10/26/2023

Medication Adherence, Healthcare Resource Utilization, and Costs Among Medicaid Beneficiaries With Schizophrenia Treated With Once-monthly Paliperidone Palmitate or Once-every-three-months Paliperidone Palmitate

Background: Antipsychotics with reduced dosing frequency may improve adherence and clinical outcomes for patients with schizophrenia. This study compared adherence, persistence, healthcar...

Maryia Zhdanava , MA;

Maria-Helene Lafeuille , MA;

Kruti Joshi , MPH, MD;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Aurelie Cote ;

Maude Vermette-Laforme , BSc;

10/08/2020

This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: There is limited literature on treatment patterns, healthcare resourc...

Charmi Patel , BS , RN, BSN, MPH;

Antoine C. El Khoury , PhD;

Ahong Huang , BS , MS;

Kruti Joshi , MPH, MD;

Li Wang , MS, MBA, PhD, MA;

Onur Baser , PhD, ScM, BS , MS;

03/01/2019

Cluster Analysis of Care Pathways in Major Depressive Disorder With Suicidal Ideation or Probable Suicide Attempt

BACKGROUND: To understand heterogeneity among the population with major depressive disorder (MDD) and suicidal ideation (SI) or attempt (SA) (MDD+SI/SA), clusters were identified through ...

Laura Morrison , MPH;

Maryia Zhdanava , MA;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Cheryl Neslusan , PhD;

Tom Cornwall , PhD;

Maude Vermette-Laforme , BSc;

Abigail Nash , MD, PhD;

10/08/2020

Real-World Outcomes Post-Transition to Once-Every-Three-Month Paliperidone Palmitate in Patients With Schizophrenia Within US Commercial and Managed Care Plans

Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...

Antoine C. El Khoury , PhD;

Bruno Emond , MA;

Maryia Zhdanava , MA;

Kruti Joshi , MPH, MD;

Charmi Patel , BS , RN, BSN, MPH;

Patrick Lefebvre , MA;

Laura Morrison , MPH;

Dominic Pilon , MA;

Neeta Tandon , MA;

03/01/2019

A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on use of Long-acting Injectable Anti-psychotic Medications

Background and Objectives: Many clinical practice guidelines (CPGs) on the treatment of schizophrenia have been updated. Aiming to review current CPGs, focusing specifically on long-actin...

Kruti Joshi , MPH, MD;

Edward S. Kim , MD, FACP, MBA;

Christoph U. Correll , MD;

Charmi Patel , BS , RN, BSN, MPH;

Amber Martin , BS;

Rebecca Goulding , PhD;

Jennifer Kern Sliwa , PharmD, BCPP;

Emma Schiller , BA;

Carmella Benson , MSc, MS, MSHP;

10/08/2020

Is Increased Severity of Major Depressive Disorder Associated With Incremental Economic Burden in Privately Insured US Patients With Treatment Resistant Depression?

Background: Among patients with major depressive disorder (MDD), those with treatment-resistant depression (TRD) have a higher economic burden. However, healthcare resource utilization (H...

Laura Morrison , MPH;

Patrick Lefebvre , MA;

John J. Sheehan , PhD, MBA, RPh;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Holly Szukis , MPH;

Maryia Zhdanava , MA;

03/01/2019

Characteristics of Commercially Insured Patients Initiated on Esketamine Nasal Spray in a Real-World Setting

BACKGROUND: Esketamine nasal spray was approved for adults with treatment-resistant depression on 03/05/2019. Real-world data on patients initiated on esketamine is limited. METHODS: Adu...

Laura Morrison , MPH;

Swapna Karkare , MS;

Abigail Nash , MD, PhD;

Maryia Zhdanava , MA;

Aditi Shah , MA;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

10/08/2020

Treatment Discontinuation of Long-Acting Injectables or Oral Atypical Antipsychotics Among Medicaid Recipients With Schizophrenia

OBJECTIVE: Compare treatment discontinuation of atypical long-acting injectables (LAIs) and oral atypical antipsychotics (OAA) in patients with schizophrenia.

Xue Song , PhD;

Antoine C. El Khoury , PhD;

Matthew Brouillette , MPH;

Kruti Joshi , MPH, MD;

David Smith , PhD, MD, MBBS, DPM;

03/01/2019

How Well Do Real-World Clinical And Demographic Characteristics Predict Patient Health Questionnaire-9 Scores Among Patients With Treatment-Resistant Depression?

Background: Many real-world databases do not capture the Patient Health Questionnaire-9 (PHQ-9), a self-reported questionnaire used to measure depression severity. We created a model to p...

Xing Liu , MA;

Eros Papademetriou , MA;

Kruti Joshi , MPH, MD;

Ella Daly , MB, BCh, BAO;

Ravi Potluri ;

David Rotter ;

Harsh Kuvadia ;

John J. Sheehan , PhD, MBA, RPh;

Anandaroop Dasgupta , PhD, MS;

11/22/2019